Please use this identifier to cite or link to this item:
|Title:||Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer||Authors:||El Hachem, Georges
|Affiliations:||Faculty of Medicine||Keywords:||CDK 4/6 inhibitors
Luminal breast cancer
Hormone receptor positive
|Issue Date:||2021||Publisher:||Taylor & Francis Online||Part of:||Expert Review of Anticancer Therapy||Volume:||21||Issue:||1||Start page:||81||End page:||92||Abstract:||
The field of metastatic luminal breast cancer (hormone receptor positive, HER-2 negative) is dynamic and evolving, harboring some of the most significant therapeutic advances in medical oncology. Over the last decade, many pivotal trials showed excellent results with drastic improvements in survival as well as the quality of life of metastatic luminal breast cancer patients.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/5219||ISSN:||14737140||DOI:||10.1080/14737140.2020.1834385||Ezproxy URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Jun 25, 2022
checked on Jul 1, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.